The ASCO Post covered ilixadencel and the MERECA study in an article titled, “Off-the-Shelf Dendritic Vaccine Shows Benefit… Read more
Our Chief Operating Officer, Sijme Zeilemaker, presented at the RedEye Fight Cancer Seminar this morning. Click here to… Read more
Immunicum was recently covered in BioStock’s article, “Immunicum’s advancements with ilixadencel highlighted in year-end report” For access to… Read more
Immunicum was recently covered in BioStock’s article, “Immunicum presenterade positiva fas II-data från MERECA” For access to the… Read more
RedEye interviewed Immunicum’s COO, Sijme Zeilemaker following the presentation of the updated MERECA results at ASCO-SITC: RedEye Interview
Edison report: https://www.edisongroup.com/publication/updated-phase-ii-mereca-data-positive/26121 EdisonTV interview: https://www.edisongroup.com/edison-tv/executive-interview-immunicum-2/
Immunicum’s Interim CEO, Alex Karlsson-Parra provides background & insights on the updated Phase II MERECA results in this… Read more
Click here to view our most recent corporate presentation: February 2020
A randomized phase II study with ilixadencel, a cell-based immune primer, plus sunitinib versus sunitinib alone in synchronous… Read more
Immunicum/technology/publications
